Format
Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 635

1.

The mitochondria-targeting peptide elamipretide diminishes circulating HtrA2 in ST-segment elevation myocardial infarction.

Hortmann M, Robinson S, Mohr M, Mauler M, Stallmann D, Reinöhl J, Duerschmied D, Peter K, Carr J, Gibson CM, Bode C, Ahrens I.

Eur Heart J Acute Cardiovasc Care. 2017 May 1:2048872617710789. doi: 10.1177/2048872617710789. [Epub ahead of print]

PMID:
28534645
2.

Platelet lipidomics: a window of opportunity to assess cardiovascular risk?

McFadyen JD, Meikle PJ, Peter K.

Eur Heart J. 2017 May 17. doi: 10.1093/eurheartj/ehx258. [Epub ahead of print] No abstract available.

PMID:
28520938
3.

Evolution of Australian Percutaneous Coronary Intervention (from the Melbourne Interventional Group [MIG] Registry).

Yeoh J, Yudi MB, Andrianopoulos N, Yan BP, Clark DJ, Duffy SJ, Brennan A, New G, Freeman M, Eccleston D, Sebastian M, Reid CM, Wilson W, Ajani AE; Melbourne Interventional Group..

Am J Cardiol. 2017 Apr 12. pii: S0002-9149(17)30629-X. doi: 10.1016/j.amjcard.2017.03.258. [Epub ahead of print]

PMID:
28495431
4.

A single-chain antibody-CD39 fusion protein targeting activated platelets protects from cardiac ischaemia/reperfusion injury.

Ziegler M, Hohmann JD, Searle AK, Abraham MK, Nandurkar HH, Wang X, Peter K.

Eur Heart J. 2017 May 2. doi: 10.1093/eurheartj/ehx218. [Epub ahead of print]

PMID:
28472483
5.

Cytotoxic Lymphocytes and Atherosclerosis. Significance, Mechanisms, and Therapeutic challenges.

Kyaw T, Peter K, Yi L, Tipping P, Toh BH, Bobik A.

Br J Pharmacol. 2017 May 4. doi: 10.1111/bph.13845. [Epub ahead of print]

PMID:
28471481
6.

Molecular imaging of activated platelets via antibody-targeted ultra-small iron oxide nanoparticles displaying unique dual MRI contrast.

Ta HT, Li Z, Hagemeyer CE, Cowin G, Zhang S, Palasubramaniam J, Alt K, Wang X, Peter K, Whittaker AK.

Biomaterials. 2017 Jul;134:31-42. doi: 10.1016/j.biomaterials.2017.04.037. Epub 2017 Apr 22.

PMID:
28453956
7.

Molecular Imaging of Atherothrombotic Diseases: Seeing Is Believing.

Wang X, Peter K.

Arterioscler Thromb Vasc Biol. 2017 Jun;37(6):1029-1040. doi: 10.1161/ATVBAHA.116.306483. Epub 2017 Apr 27. Review.

PMID:
28450298
8.

A Unique Recombinant Fluoroprobe Targeting Activated Platelets Allows In Vivo Detection of Arterial Thrombosis and Pulmonary Embolism Using a Novel Three-Dimensional Fluorescence Emission Computed Tomography (FLECT) Technology.

Lim B, Yao Y, Huang AL, Yap ML, Flierl U, Palasubramaniam J, Zaldivia MTK, Wang X, Peter K.

Theranostics. 2017 Feb 26;7(5):1047-1061. doi: 10.7150/thno.18099. eCollection 2017.

9.

Functionalized polymer-iron oxide hybrid nanofibers: Electrospun filtration devices for metal oxyanion removal.

Peter KT, Johns AJ, Myung NV, Cwiertny DM.

Water Res. 2017 Jun 15;117:207-217. doi: 10.1016/j.watres.2017.04.007. Epub 2017 Apr 4.

PMID:
28399482
10.

The effects of particle size, shape, density and flow characteristics on particle margination to vascular walls in cardiovascular diseases.

Ta HT, Truong NP, Whittaker AK, Davis TP, Peter K.

Expert Opin Drug Deliv. 2017 Apr 13:1-13. doi: 10.1080/17425247.2017.1316262. [Epub ahead of print]

PMID:
28388248
11.

Development of a novel strategy to target CD39 antithrombotic activity to the endothelial-platelet microenvironment in kidney ischemia-reperfusion injury.

Sashindranath M, Dwyer KM, Dezfouli S, Selan C, Crikis S, Lu B, Yuan Y, Hickey MJ, Peter K, Robson SC, Cowan PJ, Nandurkar HH.

Purinergic Signal. 2017 Jun;13(2):259-265. doi: 10.1007/s11302-017-9558-3. Epub 2017 Mar 25.

PMID:
28343356
12.

Metabolic Hallmarks of Tumor and Immune Cells in the Tumor Microenvironment.

Renner K, Singer K, Koehl GE, Geissler EK, Peter K, Siska PJ, Kreutz M.

Front Immunol. 2017 Mar 8;8:248. doi: 10.3389/fimmu.2017.00248. eCollection 2017. Review.

13.

Prediction of acute coronary syndromes by urinary proteome analysis.

Htun NM, Magliano DJ, Zhang ZY, Lyons J, Petit T, Nkuipou-Kenfack E, Ramirez-Torres A, von Zur Muhlen C, Maahs D, Schanstra JP, Pontillo C, Pejchinovski M, Snell-Bergeon JK, Delles C, Mischak H, Staessen JA, Shaw JE, Koeck T, Peter K.

PLoS One. 2017 Mar 8;12(3):e0172036. doi: 10.1371/journal.pone.0172036. eCollection 2017.

14.

Shear-sensitive nanocapsule drug release for site-specific inhibition of occlusive thrombus formation.

Molloy CP, Yao Y, Kammoun H, Bonnard T, Hoefer T, Alt K, Tovar-Lopez F, Rosengarten G, Ramsland PA, van der Meer AD, van den Berg A, Murphy AJ, Hagemeyer CE, Peter K, Westein E.

J Thromb Haemost. 2017 May;15(5):972-982. doi: 10.1111/jth.13666. Epub 2017 Apr 9.

PMID:
28267256
15.

Novel Thrombolytic Drug Based on Thrombin Cleavable Microplasminogen Coupled to a Single-Chain Antibody Specific for Activated GPIIb/IIIa.

Bonnard T, Tennant Z, Niego B, Kanojia R, Alt K, Jagdale S, Law LS, Rigby S, Medcalf RL, Peter K, Hagemeyer CE.

J Am Heart Assoc. 2017 Feb 3;6(2). pii: e004535. doi: 10.1161/JAHA.116.004535.

16.

Patients with Bernard-Soulier syndrome and different severity of the bleeding phenotype.

Boeckelmann D, Hengartner H, Greinacher A, Nowak-Göttl U, Sachs UJ, Peter K, Sandrock-Lang K, Zieger B.

Blood Cells Mol Dis. 2017 Jan 22. pii: S1079-9796(16)30281-9. doi: 10.1016/j.bcmd.2017.01.010. [Epub ahead of print]

PMID:
28131619
17.

Transitional changes in the CRP structure lead to the exposure of proinflammatory binding sites.

Braig D, Nero TL, Koch HG, Kaiser B, Wang X, Thiele JR, Morton CJ, Zeller J, Kiefer J, Potempa LA, Mellett NA, Miles LA, Du XJ, Meikle PJ, Huber-Lang M, Stark GB, Parker MW, Peter K, Eisenhardt SU.

Nat Commun. 2017 Jan 23;8:14188. doi: 10.1038/ncomms14188.

18.

Antithymocyte Globulin Induces a Tolerogenic Phenotype in Human Dendritic Cells.

Roider T, Katzfuß M, Matos C, Singer K, Renner K, Oefner PJ, Dettmer-Wilde K, Herr W, Holler E, Kreutz M, Peter K.

Int J Mol Sci. 2016 Dec 11;17(12). pii: E2081.

19.

Renal Denervation Reduces Monocyte Activation and Monocyte-Platelet Aggregate Formation: An Anti-Inflammatory Effect Relevant for Cardiovascular Risk.

Zaldivia MT, Rivera J, Hering D, Marusic P, Sata Y, Lim B, Eikelis N, Lee R, Lambert GW, Esler MD, Htun NM, Duval J, Hammond L, Eisenhardt SU, Flierl U, Schlaich MP, Peter K.

Hypertension. 2017 Feb;69(2):323-331. doi: 10.1161/HYPERTENSIONAHA.116.08373. Epub 2016 Dec 12.

PMID:
27956575
20.

Toll-Like Receptor (TLR)4 and MyD88 are Essential for Atheroprotection by Peritoneal B1a B Cells.

Hosseini H, Li Y, Kanellakis P, Tay C, Cao A, Liu E, Peter K, Tipping P, Toh BH, Bobik A, Kyaw T.

J Am Heart Assoc. 2016 Nov 14;5(11). pii: e002947.

Supplemental Content

Loading ...
Support Center